Quantcast

Latest Olaparib Stories

2010-10-27 08:00:00

BURLINGTON, Mass., Oct. 27 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, through 2019, the combined sales of seven new therapies for the treatment of breast cancer will total nearly $5 billion in the United States, France, Germany, Italy, Spain, United Kingdom and Japan. Among the emerging therapies for the indication, surveyed experts are particularly enthusiastic about agents in the Poly...

2010-09-30 19:24:45

Patients with triple negative breast cancer that also have mutations in the BRCA gene appear to have a lower risk of recurrence, compared to those with the same disease without the deleterious genetic mutation, according to researchers at The University of Texas MD Anderson Cancer Center. The findings may offer a direction for study of personalized therapy in this select group of triple negative breast cancer patients, as well as highlight the unique need for genetic testing in a patient...

2010-08-12 14:15:29

Cedars-Sinai participates in international study suggesting that the underlying genetic weakness of cancer, not the organ of origin, is key to effective therapy Understanding the underlying genetic weakness of certain types of cancer may lead to targeted therapy and provide the key to effective treatment, a new study suggests. An international consortium of researchers has shown that an investigational drug, Olaparib, can reduce the size of tumors in women with advanced hereditary ovarian...

2010-07-06 12:11:05

New strategy holds promise for fewer patient side effects A novel therapy designed to attack tumors in patients with a genetic mutation in either BRCA1 or BRCA2, slowed tumor growth in 85 percent of advanced breast cancer patients treated in a small study, researchers report in the July 6 issue of the Lancet. "That is really an enormous response rate in a population of patients who have received a median of three prior therapies," says study co-author Susan M. Domchek, MD, associate professor...

2010-04-06 08:15:00

WALTHAM, Mass., April 6 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the ovarian cancer drug market -- driven by the approval and rapid uptake of Roche/Genentech/Chugai's Avastin -- will more than triple from $449 million in 2008 to just under $1.5 billion in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. The Pharmacor 2010 findings from the topic...

2010-04-06 07:21:26

Women with breast cancer before age 55 who carry an inherited mutation in the breast cancer susceptibility genes BRCA1 or BRCA2 are four times more likely to develop cancer in the breast opposite, or contralateral, to their initial tumor as compared to breast cancer patients without these genetic defects. These findings, by Fred Hutchinson Cancer Research Center breast cancer epidemiologist Kathleen Malone, Ph.D., and colleagues, were published online April 5 in the Journal of Clinical...

2010-02-24 07:00:00

WALTHAM, Mass., Feb. 24 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in 2018, Sanofi-Aventis's BSI-201 will garner sales of $1.7 billion in the triple negative breast cancer drug market in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. Owing to the improvement in overall survival rates it has demonstrated in clinical trials and the need for novel targeted...

2010-02-22 13:18:34

Ovarian and breast cancer treatments being developed that mix a protein inhibitor and traditional anticancer drugs are showing signs of success, according to a new review for Faculty of 1000 Biology Reports. Susan Bates and Christina Annunziata looked at several recent papers on this form of treatment, which takes advantage of the synthetic lethality of BRCA (breast cancer susceptibility genes) and poly-ADP ribose polymerase (PARP) proteins to attack cancerous cells whilst sparing healthy...

2010-01-25 15:15:20

Breast cancer patients who have triple negative breast cancer, an aggressive form of the disease, that has spread to other parts of the body, are being asked to participate in a clinical study of a promising new treatment called PARP inhibitors. Researchers from the Lester and Sue Smith Breast Center at Baylor College of Medicine will conduct the study at both the Baylor Clinic and the Harris County Hospital District's Ben Taub General Hospital. "This is a very important study," said Dr....

2009-12-19 00:15:25

New findings may help explain why women who carry a mutated BRCA1 gene have greater rates of infertility as well as a greater risk for breast and ovarian cancer A New York Medical College physician who specializes in restoring or preserving fertility in female cancer patients has discovered a possible link between the presence of breast cancer genes and infertility. In a paper published last week in the Journal of Clinical Oncology, Kutluk Oktay, M.D., professor of obstetrics and gynecology...


Word of the Day
holluschickie
  • A 'bachelor seal'; a young male seal which is prevented from mating by its herd's older males (mated bulls defending their territory).
This comes from the Russian word for 'bachelors.'
Related